Skip to content
Menu
Home – New Health Bulletins
Health News Statements
About
Contact
Health Newswire
Menu
Home – New Health Bulletins
Health News Statements
About
Contact
Syntrix Completes Initial SX-682 Dosing in Broad Phase 1/2 Cancer Trial Campaign Now Encompassing 5 Solid Cancer Types Plus Myelodysplastic Syndromes
27 Oct 2020